Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma
ConclusionPembrolizumab demonstrated modest single-agent activity in relapsed or refractory T-cell lymphoma. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 26, 2019 Category: Cancer & Oncology Source Type: research

Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Publication date: Available online 30 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Young-Woo Jeon, Seugyun Yoon, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Chang-Ki Min, Jong Wook Lee, Seok-Goo ChoAbstractIntroductionAllogeneic hematopoietic stem cell transplant with reduced-intensity conditioning is an effective therapeutic option for patients with refractory or relapsed aggressive non-Hodgkin lymphoma (NHL).Patients and MethodsWe retrospectively evaluated survival outcomes and the efficacy of our fludarabine/mel...
Source: Clinical Lymphoma Myeloma and Leukemia - April 21, 2019 Category: Cancer & Oncology Source Type: research

Long-term Outcomes of Modified SJCRH Total Therapy XIIIB and XV Protocols for Thai Children with Acute Lymphoblastic Leukemia
ConclusionFavorable outcomes of childhood ALL occurred using adapted SJCRH protocols perhaps because of multidisciplinary care teams and improved parent advocacy. Inferior outcomes might be prevented by illustrating predictive factors to ameliorate monitoring and care. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 20, 2019 Category: Cancer & Oncology Source Type: research

Allogeneic stem cell transplantation in patients with flt3-itd mutated aml: transplantation in cr1 is the decisive factor for good outcome
Publication date: Available online 19 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Pavel Jindra, Luděk Raida, Michal Karas, Tomáš Szotkowski, Daniel Lysák, Marcela Hrabětová, Alexandra Jungová, Kateřina Steinerová, Edgar Faber, Tomáš PapajíkAbstract:Patients with FLT3-ITD AML have a poor outcome and early allogeneic stem cell transplantation (alloSCT) seems to be only curative modality. Our data confirm the early alloSCT remains the best consolidation therapy (even for older patients) and should be performed immediately in CR1. The unsa...
Source: Clinical Lymphoma Myeloma and Leukemia - April 20, 2019 Category: Cancer & Oncology Source Type: research

Efficacy and Feasibility of Sorafenib as a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: an update
Publication date: Available online 18 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Giorgia Battipaglia, Radwan Massoud, Syed Osman Ahmed, Ollivier Legrand, Jean El Cheikh, Riad Youniss, Mahmoud Aljurf, Mohamad Mohty, Ali Bazarbachi (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 18, 2019 Category: Cancer & Oncology Source Type: research

Correlations Between Imaging Biomarkers and Proliferation Index Ki-67 in Lymphomas: A Systematic Review and Meta-Analysis
ConclusionSUVmax derived from FDG and FLT PET correlated moderately and approximately equally with Ki-67 index. On the contrary, ADC values only correlated weakly inversely and might not reliably predict Ki-67 index in lymphomas. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 17, 2019 Category: Cancer & Oncology Source Type: research

Favorable outcomes with tumor burden reduction following administration of hypomethylating agents before allogeneic hematopoietic cell transplantation in patients with higher-risk myelodysplastic syndrome
Publication date: Available online 11 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Sungwoo Park, Dong Won Baek, Sang Kyun Sohn, Jae Sook Ahn, Hyeoung Joon Kim, Ho Jin Shin, Joo Seop Chung, Sang Min Lee, Won Sik Lee, Sung Nam Lim, Yoo Jin Lee, Yunsuk Choi, Ho Sup Lee, Yoon Young Cho, Gyeong-Won Lee, Joon Ho MoonAbstractIntroductionThe clinical significance of tumor burden reduction following administration of hypomethylating agents (HMA) for transplant-eligible patients with higher-risk myelodysplastic syndrome (MDS) was evaluated.Patients and MethodsData of 79 transplant-eligible patients (
Source: Clinical Lymphoma Myeloma and Leukemia - April 12, 2019 Category: Cancer & Oncology Source Type: research

Low-Dose Lenalidomide after Non-Myeloablative Allogeneic Hematopoietic Cell Transplant with Bortezomib as GVHD Prophylaxis in High-Risk Multiple Myeloma
Publication date: Available online 8 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jack Khouri, Frederic Reu, Navneet S. Majhail, Aaron Gerds, Deepa Jagadeesh, Robert Dean, Ronald Sobecks, Betty K. Hamilton, Brad Pohlman, Brian T. Hill, Donna Corrigan, Matt Kalaycio, Brian J. Bolwell, Hien D. Liu (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 9, 2019 Category: Cancer & Oncology Source Type: research

Platelet counts and risk of major bleeding with ibrutinib
Publication date: Available online 6 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Marko Lucijanic, Marko Skelin (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 7, 2019 Category: Cancer & Oncology Source Type: research

Pomalidomide Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-analysis of Phase II and Phase III Clinical Trials
This study aims to compare outcome measures of different Pom-regimens for relapsed refractory multiple myeloma.MethodsComprehensive literature search identified a total of 1374 studies. 35 studies (n=4623) met the inclusion criteria; phase II/III trial, ≥ 2 prior lines of therapy and clearly documented efficacy outcomes like overall response rate(ORR), overall survival(OS), progression free survival(PFS). Statistical analyses for meta-analysis was performed using CMA version 3 and Cochrane Q statistics (p
Source: Clinical Lymphoma Myeloma and Leukemia - April 7, 2019 Category: Cancer & Oncology Source Type: research

Nutrition-related outcomes for autologous stem cell transplant patients
Publication date: Available online 6 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Heather Lazarow, Michele Nicolo, Charlene Compher, Colleen R. Kucharczuk, Edward A. Stadtmauer, Daniel J. LandsburgAbstractMicroabstractAutologous stem cell transplant patients are at risk for malnutrition, which may be linked to negative clinical outcomes. A retrospective, observational study examined data related to 330 consecutively admitted adults. Patients at high malnutrition risk had longer hospital stays, increased nosocomial infections, and increased one-year mortality. Further studies are needed to investigate ...
Source: Clinical Lymphoma Myeloma and Leukemia - April 7, 2019 Category: Cancer & Oncology Source Type: research

Multiple Myeloma: Clinical Updates from the American Society of Hematology Annual Meeting 2018
Publication date: Available online 4 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, International Myeloma SocietyAbstractHerein, we summarize the novel clinical data for multiple myeloma (MM) that were presented in the 2019 Annual Meeting of the American Society of Hematology. Triplet regimens including lenalidomide-dexamethasone for high risk smoldering MM are effective but longer follow-up data are needed. Among transplant-eligible, newly diagnosed MM (NDMM) patients, carfilzomib- and daratumumab-based combinations are promising as effective and safe in...
Source: Clinical Lymphoma Myeloma and Leukemia - April 6, 2019 Category: Cancer & Oncology Source Type: research

The outcomes of chronic myeloid leukemia patients with molecular warning responses under imatinib according to the European LeukemiaNet (ELN) 2013 recommendations
Publication date: Available online 4 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Teoman Soysal, Ahmet Emre Eskazan, Istemi Serin, Sevil Sadri, Dilek Keskin, Nurgul Ozgur Yurttas, Selin Berk, Isil Erdogan Ozunal, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren, Zafer Baslar, Ugur Ozbek, Yildiz AydinAbstractIn the European LeukemiaNet (ELN) 2013 recommendations, chronic myeloid leukemia (CML) patients with warning response (WR) were suggested to be monitored closely continuing with the same tyrosine kinase inhibitor (TKI). Differently, the guidelines of National Comprehensive Cancer Network considers swit...
Source: Clinical Lymphoma Myeloma and Leukemia - April 6, 2019 Category: Cancer & Oncology Source Type: research

p53 and β-catenin expression predict poorer prognosis in patients with anaplastic large cell lymphoma
Publication date: Available online 5 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Aida Ibricevic Richardson, C. Cameron Yin, Wei Cui, Nianyi Li, L. Jeffrey Medeiros, Linheng Li, Da ZhangAbstractThe Wnt/β-catenin signaling pathway is a major target of p53. β-catenin/p53 co-expression predicts poorer survival in carcinoma patients. Conversely, CD99 inhibits tumor metastasis through Wnt/β-catenin pathway. We therefore assessed p53, β-catenin and CD99 by immunohistochemistry in 45 patients with systemic anaplastic large cell lymphoma (ALCL), including 20 anaplastic lymphoma kinase (ALK...
Source: Clinical Lymphoma Myeloma and Leukemia - April 6, 2019 Category: Cancer & Oncology Source Type: research

High level of serum soluble interleukin-2 receptor is associated with poor survival in patients with first relapsed or refractory peripheral T-cell lymphoma, not otherwise specified: A retrospective study
ConclusionSerum sIL-2R is a useful prognostic marker for patients with R/R-PTCL-NOS. In particular, high sIL-2R level can identify groups of patients with low-risk sIPI who have poor prognosis. Our results suggest that novel therapeutic approaches may be necessary for patients with high-risk sIPI and/or high sIL-2R level. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 6, 2019 Category: Cancer & Oncology Source Type: research

Phase II Study of the PD1-inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma
ConclusionPembrolizumab demonstrated modest single agent activity in relapsed or refractory T-cell lymphoma. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 4, 2019 Category: Cancer & Oncology Source Type: research

Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience
ConclusionHistory of CLL did not independently affect OS in t-MDS patients beyond IPSS-R score. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 3, 2019 Category: Cancer & Oncology Source Type: research

Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation
ConclusionAlthough even transient reduction in systolic function might compromise survival outcome, diastolic dysfunction predicts improved survival in patients with AML who undergo HSCT. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 3, 2019 Category: Cancer & Oncology Source Type: research

Prognostic and therapeutic value of day 14 bone marrow aspiration in adult Acute Myeloid Leukemia patients
Publication date: Available online 1 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Mosaad M. El Gammal, Hend M. Owaidat, Reham A. Rashed, Raafat Abdel Fatah, Mohamed A. SamraAbstractBackgroundEarly blast clearance to induction chemotherapy in acute myeloid leukemia (AML) is an important prognostic indicator of treatment outcome, beside genetics and molecular geneticsAimis to evaluate the prognostic value of bone marrow aspirate day 14(BMA d14) and impact on outcome and to asses timing of second induction.Patients and MethodsThis retrospective study included 303 adult AML patients managed at NCI, Cairo ...
Source: Clinical Lymphoma Myeloma and Leukemia - April 3, 2019 Category: Cancer & Oncology Source Type: research

Interferon alpha has strong anti-tumor effect in Philadelphia-negative Myeloproliferative Neoplasms
Publication date: Available online 1 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Patrizia Mondello, Cristian Di Mirto, Salvatore Cuzzocrea, Carmela Arrigo, Michael Mian, Vincenzo Pitini MAbstractBackgroundDespite the important progress in the research of myeloproliferative neoplasms (MPN), treatment options are still limited. Currently, a cytoreductive approach is the backbone treatment, with hydroxyurea (HU) being the most important agent. However, this drug is not always well tolerated and seems to be associated with a potential leukemogenic effect. A valid alternative is interferon alfa (IFN-&alph...
Source: Clinical Lymphoma Myeloma and Leukemia - April 3, 2019 Category: Cancer & Oncology Source Type: research

Multiple Myeloma: Current Advances and Future Directions
Publication date: Available online 1 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Thomas Martin, Carol Ann HuffAbstractThere have been many advances over the past decade which have dramatically changed the way we evaluate and treat patients with multiple myeloma. These advances have more than doubled the average survival for patients with multiple myeloma and have been paramount to an improved quality of life. Herein, we highlight recent changes to response assessment definitions, provide a review of minimal residual disease (MRD) testing and describe how may MRD testing may affect future goals of the...
Source: Clinical Lymphoma Myeloma and Leukemia - April 3, 2019 Category: Cancer & Oncology Source Type: research

Fibril directed therapies in systemic light chain AL Amyloidosis.
Publication date: Available online 1 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Divaya Bhutani, Siyang Leng, Suzanne LentzschAbstractAL amyloidosis is a plasma cell disorder leading to the production and extracellular deposition of abnormal immunoglobulin light chains called amyloid. The pathogenesis of the disorder is driven by an abnormal plasma cell clone producing excessive monoclonal immunoglobulin light chains which undergo deposition in various organs of the body such as heart, kidney and gastrointestinal tract. The outcome of the disease remains poor with significant morbidity and mortality ...
Source: Clinical Lymphoma Myeloma and Leukemia - April 3, 2019 Category: Cancer & Oncology Source Type: research

Incidence, clinical features, and outcomes of Langerhans cell sarcoma in the United States
ConclusionThis dual-national registry study shows that LCS is extremely rare, and has a poor prognosis. Our study demonstrates that radiation therapy may offer survival advantage in patients with loco-regional disease without bone marrow and RES involvement. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - April 3, 2019 Category: Cancer & Oncology Source Type: research

High-dose therapy and autologous hematopoietic cell transplantation as consolidation treatment for primary effusion lymphoma
ConclusionDespite the small sample size, our data show that consolidative auto-HCT is safe and could be considered for eligible PEL patients after induction chemotherapy. However, a high relapse rate is concerning and warrants incorporation of new strategies to mitigate post-transplantation relapse. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 30, 2019 Category: Cancer & Oncology Source Type: research

Lenalidomide combination therapy in relapsed/refractory diffuse large B cell lymphoma: the Italian real-life experience
We report the results of a national observational study on the use of lenalidomide combined with rituximab or dexamethasone in patients with relapsed or refractory DLBCL, in a real-life context. Forty-seven patients, median age 72.8 years, were treated with a median of 4 cycles of therapy; 29.8% of patients achieved a complete response (CR), with an overall response rate of 42.6%. A subset of patients maintained response over time; in fact, 6-year-progression free survival (PFS) and overall survival (OS) were 23% and 30%, respectively.Treatment was well tolerated. Combination of lenalidomide with rituximab or dexamethasone...
Source: Clinical Lymphoma Myeloma and Leukemia - March 30, 2019 Category: Cancer & Oncology Source Type: research

Clinical Outcomes of Fludarabine and Melphalan with a 800 cGy Total Body Irradiation Conditioning Regimen in Patients with Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Publication date: Available online 30 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Young-Woo Jeon, Seugyun Yoon, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Chang-Ki Min, Jong Wook Lee, Seok-Goo ChoAbstractIntroductionAllogeneic hematopoietic stem cell transplant (allo-HSCT) with reduced-intensity conditioning is an effective therapeutic option for patients with refractory or relapsed aggressive non-Hodgkin’s lymphoma (NHL).MethodsWe retrospectively evaluated survival outcomes and the efficacy of our Fludarab...
Source: Clinical Lymphoma Myeloma and Leukemia - March 30, 2019 Category: Cancer & Oncology Source Type: research

Optimal Time Points for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis on the Basis of European LeukemiaNet Recommendations in Chronic Myeloid Leukemia
ConclusionIrrespective of mutation frequency, failure of achievement of a cytogenetic response should be conducted with appropriate mutation analysis. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 28, 2019 Category: Cancer & Oncology Source Type: research

Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients
ConclusionDNMT3A, FLT3-ITD, and NPM1A are frequent mutations in Egyptian AML. FLT3-ITD mutations are frequent in older patients. DNMT3A and FLT3-ITD mutations were associated with an unfavorable prognosis, but the NPM1A mutation has tendency to indicate a good prognosis. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 28, 2019 Category: Cancer & Oncology Source Type: research

Oral MEK 1/2 Inhibitor Trametinib in Combination with AKT Inhibitor GSK2141795 in Patients with Acute Myeloid Leukemia with RAS Mutations: A Phase II Study
Publication date: Available online 26 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Brittany Knick Ragon, Olatoyosi Odenike, Maria R. Baer, Wendy Stock, Gautam Borthakur, Keyur Patel, Lina Han, Helen Chen, Helen Ma, Loren Joseph, Yang Zhao, Keith Baggerly, Marina Konopleva, Nitin JainAbstractWith proven single-agent activity and favorable toxicity profile of MEK-1/2 inhibition in advanced leukemia, investigation into combination strategies to overcome proposed resistance pathways is warranted. Resistance to MEK inhibition is secondary to upstream hyperactivation of RAS/RAF or activation of the PI3K/PTE...
Source: Clinical Lymphoma Myeloma and Leukemia - March 28, 2019 Category: Cancer & Oncology Source Type: research

Correlation of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with susceptibility and prognosis for multiple myemola
Publication date: Available online 25 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hongbo Wu, Ting Huang, Zhifeng Ye, Xiaoqing Fu, Keke Hu, Xuefei YangAbstractObjectiveTo explore correlation of MIR17HG polymorphism with susceptibility and prognosis of multiple myemola (MM).MethodsA total of 217 MM patients treated with high-dose melphalan combined with autologous peripheral blood stem cell transplantation (PBSCT) in our hospital were enrolled as case group, and 220 healthy people were included as control group. The Sequenom MassARRAY® iPLEX™ Gold SNP genotyping was used to detect polymorphis...
Source: Clinical Lymphoma Myeloma and Leukemia - March 26, 2019 Category: Cancer & Oncology Source Type: research

Role of p15(INK4B) methylation in patients with myelodysplastic syndromes: a systematic meta-analysis
Publication date: Available online 25 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Fang Ye, Ningning LiAbstractBackgroundTumor suppressor gene p15(INK4B) methylation has been frequently reported in myelodysplastic syndromes (MDS). However, the association between p15(INK4B) methylation and MDS remains elusive. Thus, this meta-analysis was first conducted to evaluate the clinical significance of p15(INK4B) methylation in MDS.MethodsEligible studies were identified via the online electronic databases search. The overall odds ratios (ORs) or hazard ratios (HRs) and 95% confidence intervals (95% CIs) were...
Source: Clinical Lymphoma Myeloma and Leukemia - March 26, 2019 Category: Cancer & Oncology Source Type: research

Study on the prognostic value of aberrant antigen in patients with acute B lymphocytic leukemia
Publication date: Available online 25 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jun Liu, Xu Tan, Ying-Ying Ma, Yao Liu, Li Gao, Lei Gao, PeiYang Kong, Xian-Gui Peng, Xi Zhang, Cheng ZhangAbstractApproximately 30-60% of acute B-lymphocytic leukemia(B-ALL) patients show refractory or relapse,which is one of the major causes of death in B-ALL patients,the methods on the treatment of relapsed/refractory B-ALL (R/R B-ALL) is limited.The chimeric antigen receptors redirected T cells (CAR-T cells) has showed strong anti-leukemia role for B-ALL.About 90% of patients with R/R B-ALL treated with CD19-CART ce...
Source: Clinical Lymphoma Myeloma and Leukemia - March 26, 2019 Category: Cancer & Oncology Source Type: research

Future of personalized therapy targeting aberrant signaling pathways in multiple myeloma
Publication date: Available online 25 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Faiz Anwer, Kevin Mathew Gee, Ahmad Iftikhar, Mirza Baig, Atlantis Dawn Russ, Sabina Saeed, Muhammad Abu Zar, Faryal Razzaq, Jennifer Carew, Steffan Nawrocki, Hussam Al-Katab, Nadia Nunes Cavalcante, Ali McBride, Jason Valent, Christy SamarasAbstractMultiple myeloma (MM) is genetically complex disease. Identification of mutations and aberrant signaling pathways that contribute to the progression of MM and drug resistance has potential to lead to specific targets and personalized treatment. Aberrant signal pathways inclu...
Source: Clinical Lymphoma Myeloma and Leukemia - March 26, 2019 Category: Cancer & Oncology Source Type: research

Minimal residual disease and survival outcomes in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.
Publication date: Available online 23 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Stefano Molica, Diana Giannarelli, Emili MontserratAbstractBackgroundChronic lymphocytic leukemia (CLL) patients who achieve undetectable minimal residual disease (U-MRD) (i.e.,
Source: Clinical Lymphoma Myeloma and Leukemia - March 25, 2019 Category: Cancer & Oncology Source Type: research

Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma
Publication date: Available online 23 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hiroshi Ureshino, Kazuharu Kamachi, Shinya KimuraAbstractMogamulizumab, a defucosylated humanized monoclonal antibody against C–C chemokine receptor 4 (CCR4), has been approved for the treatment of relapsed adult T-cell leukemia/lymphoma (ATL). Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more effecacy in relapsed ATL making mogamulizumab a promising therapeutic agent. However, mogamulizumab could increase graft-versus-host disease, resulting in poor survival outcome in allogenic st...
Source: Clinical Lymphoma Myeloma and Leukemia - March 23, 2019 Category: Cancer & Oncology Source Type: research

SOHO State of the Art Updates and Next Questions: Myelofibrosis
Publication date: Available online 22 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kristen Pettit, Srdan Verstovsek, Moshe TalpazAbstractThe discovery of a mutation in the Janus Kinase 2 (JAK2) gene in 2005 spurred significant progress in the field of myeloproliferative neoplasm (MPNs). A comprehensive description of genomic factors at play in the malignant clone in MPNs, particularly myelofibrosis (MF), have recently led to more precise, personalized prognostic tools. Despite this, understanding of the disease pathogenesis remains relatively limited. We continue to lack a detailed description of the ...
Source: Clinical Lymphoma Myeloma and Leukemia - March 22, 2019 Category: Cancer & Oncology Source Type: research

Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study
Publication date: Available online 23 January 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Krzysztof Mądry, Karol Lis, Przemysław Biecek, Magda Młynarczyk, Jagoda Rytel, Michał Górka, Piotr Kacprzyk, Magdalena Dutka, Marek Rodzaj, Łukasz Bołkun, Dorota Krochmalczyk, Ewa Łątka, Joanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Wanda Knopińska-Posłuszny, Anna Kopińska, Edyta Subocz, Anna Masternak, Renata Guzicka-Kazimierczak, Lidia GilAbstractBackgroundMyelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) patients, including those treated wit...
Source: Clinical Lymphoma Myeloma and Leukemia - March 19, 2019 Category: Cancer & Oncology Source Type: research

Atypical CD4+/CD8+ Lymphocytosis and Prolonged Pancytopenia Associated with Human Herpesvirus 6 Reactivation after Autologous Peripheral Blood Stem Cell Transplantation
ConclusionThis instructive case demonstrates that HHV6 reactivation after autologous PBSCT can be associated with atypical lymphocytosis of characteristic CD4+/CD8+ cells and subsequent prolonged pancytopenia. HHV6 is known to induce expression of CD4 in CD8+ lymphocytes, and that viral reactivation likely led to the observed CD4+/CD8+ lymphocytosis. As autologous HCT remains a component of MM comprehensive therapy, transplant infectious diseases specialists and HCT physicians are encouraged to have a low index of suspicion for HHV6 reactivation when assessing MM patients who develop persistent fevers, rashes, atypical lym...
Source: Clinical Lymphoma Myeloma and Leukemia - March 17, 2019 Category: Cancer & Oncology Source Type: research

Characteristics of Waldenström Macroglobulinemia in Koreans According to Mutational Status of MYD88 and CXCR4: Analysis by Ultra-Deep Sequencing
Publication date: Available online 15 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Dong Woo Shin, Sung-Min Kim, Jung-Ah Kim, Hee Sue Park, Sang Mee Hwang, Kyongok Im, Sungsik Kim, Jinhyun Kim, Sunghoon Kwon, Sung-Soo Yoon, Dong Soon LeeAbstractBackgroundLittle is known about the mutational frequency of MYD88 and CXCR4 and the corresponding characteristics in Asians afflicted with Waldenström Macroglobulinemia (WM). We investigated the characteristics of WM according to mutational status of MYD88/CXCR4, and attempted to determine the lineage commitment among hematopoietic cells by MYD88L265P singl...
Source: Clinical Lymphoma Myeloma and Leukemia - March 17, 2019 Category: Cancer & Oncology Source Type: research

Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma
ConclusionTaken together, our data have demonstrated that a CIS is a benign phenomenon and correlates with a reduced disease burden and enriched immune repertoire beyond the B-cell compartment. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 14, 2019 Category: Cancer & Oncology Source Type: research

Overall Survival Trends and Clinical Characteristics of Plasmacytoma in the United States: A National Cancer Database Analysis
ConclusionsThis is the largest study examining outcomes of patients with plasmacytoma using a large database analysis, revealing unique aspects of P-EM versus P-bone and underutilization of radiation treatment. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 14, 2019 Category: Cancer & Oncology Source Type: research

Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma with Alectinib
We report the case of a patient with ALK translocated ALCL with CNS involvement who developed debilitating neuropathy after chemotherapy and was treated with alectinib at relapse. The patient had a complete response after 6 weeks which has continued for 6 months allowing him to undergo an allogeneic stem cell transplant. To our knowledge, this is the first published case report of a patient with ALCL successfully treated with alectinib. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 12, 2019 Category: Cancer & Oncology Source Type: research

Correlations between imaging biomarkers and proliferation index Ki 67 in lymphomas – A systematic review and meta analysis
Publication date: Available online 11 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hans-Jonas Meyer, Andreas Wienke, Alexey SurovAbstractFew studies investigated relationships between positron emission tomography (PET) as well as Diffusion-weighted imaging (DWI) with proliferating index Ki 67 in lymphomas. The aim of the present analysis was to review the published results and perform a meta analysis to provide data of the associations between standardized uptake values (SUV) derived from PET as well as apparent diffusion coefficients (ADC) derived from DWI with Ki 67 index in lymphomas. MEDLINE libra...
Source: Clinical Lymphoma Myeloma and Leukemia - March 12, 2019 Category: Cancer & Oncology Source Type: research

Racial and Socioeconomic Disparities in Mantle Cell Lymphoma
Publication date: Available online 12 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Nikesh N. Shah, Yizhao Xi, Yuan Liu, Jean L. Koff, Christopher R. Flowers, Madhusmita Behera, Jonathon B. CohenAbstractBackgroundWhile race and socioeconomic factors are associated with outcome in many malignancies, few studies have examined the impact of race and socioeconomic status (SES) on patients with mantle cell lymphoma (MCL).MethodsWe used the National Cancer Database to identify patients with MCL diagnosed between 2004 and 2013. Chi-square and ANOVA were used to assess associations of covariates with race/ethn...
Source: Clinical Lymphoma Myeloma and Leukemia - March 12, 2019 Category: Cancer & Oncology Source Type: research

Anthracycline induced cardiotoxicity in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
ConclusionsWhile even transient reduction in systolic function may compromise survival outcome, diastolic dysfunction predicts improved survival in patients with AML undergoing HSCT. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 12, 2019 Category: Cancer & Oncology Source Type: research

Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes (MDS) after Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared to Patients with De Novo MDS: A Single-Institution Experience
ConclusionHistory of CLL did not independently impact OS in t-MDS patients beyond IPSS-R. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 12, 2019 Category: Cancer & Oncology Source Type: research

Prognostic And Predictive Impact Of Ighv Mutational Status And Load In Chronic Lymphocytic Leukemia: Focus On Fcr And Br Treatments
We reported that unmutated (U-IGHV) cases were characterized by a significant shorter progression free survival (PFS) and overall survival (p
Source: Clinical Lymphoma Myeloma and Leukemia - March 12, 2019 Category: Cancer & Oncology Source Type: research

When monoclonal gammopathy is of renal significance: A case study of crystalglobulinemia from Chicago Multiple Myeloma Rounds
Publication date: Available online 8 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Brendan A. Gilmore, Roger A. Rodby, David Cimbaluk, Parameswaran Venugopal, Pritesh Patel, Kevin Barton, Patrick Hagen, Tulio Rodriguez, Luis Sumoza, Michael R. Bishop, Binod Dhakal, Parameswaran Hari, Agne Paner (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 9, 2019 Category: Cancer & Oncology Source Type: research

Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial
ConclusionThe combination was relatively well tolerated, with no additional observed toxicity to single-agent lenalidomide. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2019 Category: Cancer & Oncology Source Type: research

Day +100 Platelet Count Predicts Survival After Allogeneic Hematopoietic Stem-Cell Transplantation in Children With Hematologic Malignancies
Publication date: Available online 15 January 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hisham Moneib, Hanafy Hafez, Amr Abdalla, Omneya Hassanain, Leslie Lehmann, Alaa el HaddadAbstractIntroductionRecovery of platelet count by day 100 after hematopoietic stem-cell transplantation (HSCT) is affected by many factors and has been reported to be a predictor of overall survival (OS) in a variety of diseases and donor types. We investigated the correlation between day +100 platelet count and OS after allogeneic HSCT in a relatively homogeneous cohort of pediatric patients with hematologic malignancies.Pa...
Source: Clinical Lymphoma Myeloma and Leukemia - March 5, 2019 Category: Cancer & Oncology Source Type: research